Icatibant: Difference between revisions
Kurtucla05 (talk | contribs) (Created page with "==General== *Type: Bradykinin receptor antagonist *Dosage Forms: 30mg *Routes of Administration: Subcutaneous *Common Trade Names: Firazyr ==Adult Dosing== *30mg subcutaneous...") |
(No difference)
|
Revision as of 16:35, 7 August 2015
General
- Type: Bradykinin receptor antagonist
- Dosage Forms: 30mg
- Routes of Administration: Subcutaneous
- Common Trade Names: Firazyr
Adult Dosing
- 30mg subcutaneous
- Max 90mg/24 hours
Pediatric Dosing
not available (8/2015)
Special Populations
- Pregnancy Rating: C
- Lactation risk: safety unknown
- Renal Dosing
- Hepatic Dosing
Contraindications
- Allergy to class/drug
Adverse Reactions
Serious
- Caution if acute MI
- Caution if unstable angina
- Caution if recent stroke
Common
Pharmacology
- Half-life: 1.4h
- Metabolism: Proteolytic degradation
- Excretion: Urine 10% unchanged
- Mechanism of Action: selectively antagonizes bradykinin B2 receptor
Comments
- NEJM article 2/2015 randomized 27 people with ACEi induced angioedema to icatibant vs std therapy (Prednisone 500mg + Clemastine 2mg) looking at time to resolution.
RESULTS- significantly shorter (8 hrs vs 27.1 hrs) in icatibant group.
- Cost according to Goodrx= $9,000/dose (on 8/7/2015)